Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: Gastric cancer (GC) has a poor prognosis, considerable cellular heterogeneity, and ranks fifth among malignant tumours. Understanding the tumour microenvironment (TME) and intra-tumor heterogeneity (ITH) may lead to the development of novel GC treatments.
Methods: The single-cell RNA sequencing (scRNA-seq) dataset was obtained from the Gene Expression Omnibus (GEO) database, where diverse immune cells were isolated and re-annotated based on cell markers established in the original study to ascertain their individual characteristics.
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI).
ESMO Open
January 2025
AUSL-IRCCS Clinical Cancer Center of Reggio Emilia, Reggio Emilia, Italy.
Background: Non-metastatic pancreatic ductal adenocarcinoma (PDAC) presents a challenging scenario: the rarity of the disease, the limited number of completed prospective trials, and the shortcomings of comparability across series produce several controversial topics and unanswered questions. Guideline recommendations usually include all the different therapeutic options, de facto transferring to the multidisciplinary team the responsibility on the final decision. This secondary analysis of the GARIBALDI study was aimed to explore the correlation of center type, self-declared volume, and commitment with the overall survival (OS) in patients with non-metastatic PDAC.
View Article and Find Full Text PDFSOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review.
Clin Lymphoma Myeloma Leuk
November 2024
Memorial Sloan Kettering Cancer Center, New York City, NY. Electronic address:
Article Synopsis
- Older adults with diffuse large B-cell lymphoma (DLBCL) face unique challenges and poorer outcomes, highlighting the need for tailored care strategies.
- Geriatric assessment (GA) tools, like simplified GA (sGA), help categorize patients into fit, unfit, and frail groups to guide treatment decisions, including dose adjustments for chemotherapy.
- New treatment options, including CAR-T cell therapy and bispecific antibodies, are evolving to better serve older adults, particularly those who are unable to tolerate traditional therapies or who experience relapse after initial treatment.
A meta-analysis and systematic review of randomized controlled trials in combination gemcitabine with erlotinib in the pancreatic cancer.
Chin Clin Oncol
October 2024
Department of Pharmacology, School of Pharmacy, Gannan Medical University, Ganzhou Cancer Precision Medicine Engineering Research Center, Ganzhou, China.
Article Synopsis
- - The study reviews the effectiveness of combining gemcitabine and erlotinib (Gem-Erlo) for pancreatic cancer treatment, noting mixed results from past randomized controlled trials (RCTs) regarding its benefits over standard chemotherapy.
- - Comprehensive literature analysis included seven RCTs and 2,152 patients, focusing on various performance metrics such as disease control rate (DCR), overall survival (OS), and progression-free survival (PFS).
- - Findings indicate that while Gem-Erlo enhances DCR, it does not significantly improve overall survival, progression-free survival, or response rate compared to gemcitabine alone.
Overall burden and impact on health-related quality of life associated with intravesical treatment of patients with non-muscle invasive bladder cancer in the United States.
Curr Med Res Opin
November 2024
Analysis Group, Inc, Montreal, Quebec, Canada.
Background: This study aimed to describe the life impacts of intravesical therapies for non-muscle invasive bladder cancer (NMIBC) from a patient perspective.
Methods: A cross-sectional online survey design was used. Adults with NMIBC (and no other cancer) treated intravesically in the prior 12 months were recruited from US patient online communities.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!